Device type · CIT
Nadh Oxidation/Nad Reduction, Ast/Sgot
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
CIT
Clinical Chemistry
Device class
Class II
FDA decisions since 2015
0
510(k), De Novo and PMA
Adverse event reports
5
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Nadh Oxidation/Nad Reduction, Ast/Sgot
- Product code
- CIT
- Device class
- Class II
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1100
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for CIT
Latest FDA decisions
No 510(k), De Novo or PMA decisions for this product code since 2015.
Reports received
5
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
5
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 1 | 0 | 0 | 0 |
| Feb 24 | 1 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 1 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 2 | 0 | 0 | 0 |
| Oct 24 | 1 | 0 | 0 | 0 |
| Nov 24 | 1 | 0 | 0 | 0 |
| Dec 24 | 1 | 0 | 0 | 0 |
| Jan 25 | 2 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 3 | 0 | 0 | 0 |
| May 25 | 1 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 1 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 1 | 0 | 0 | 0 |
| Nov 25 | 2 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 1 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 1 | 0 | 0 | 0 |
| May 26 | 1 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- High Test Results2
- Incorrect, Inadequate or Imprecise Result or Readings2
- Output Problem2
1 more in this ranking with a free account
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions5
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- RX Daytona Plus (without ISE)- IVD Clinical Chemistry Analyser (1) RX4041, (2) RX4041R (refurbished)Open, Classified
Z-0199-2024 · Started Sep 6, 2023 · Posted by FDA Oct 31, 2023
Reason given: RX Parameter rerun settings (Sample Volume Low/High), and Dilutions used for Auto reruns, not meeting sample re-run conditions when samples are above or below assay range and may result i issues with the re-run feature conditions when incorrectly. Potential to report incorrectly.
Cause as FDA categorized it: Under Investigation by firm
Siemens Healthcare Diagnostics, Inc.
Z-1651-2018 · Started Jun 29, 2017
Reason given: Various assays used to measure different chemical levels in blood, urine, or cerebrospinal fluid may interfere with the drugs sulfasalazine and/or sulfapyridine causing falsely elevated or falsely depressed results.
Cause as FDA categorized it: Device Design
Siemens Healthcare Diagnostics, Inc.
Z-1657-2018 · Started Jun 29, 2017
Reason given: Various assays used to measure different chemical levels in blood, urine, or cerebrospinal fluid may interfere with the drugs sulfasalazine and/or sulfapyridine causing falsely elevated or falsely depressed results.
Cause as FDA categorized it: Device Design
10 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.